FRA
RDY icon

Front Row Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

Front Row Advisors’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-510
Closed -$5K – 989
2020
Q2 		$5K Buy
510
+145
+40% +$1.48K ﹤0.01% 640
2020
Q1 		$4K Sell
365
-390
-52% -$3.25K ﹤0.01% 683
2019
Q4 		$6K Sell
755
-5
-0.7% -$39 ﹤0.01% 587
2019
Q3 		$6K Buy
760
+195
+35% +$1.45K ﹤0.01% 564
2019
Q2 		$4K Buy
565
+120
+27% +$943 ﹤0.01% 668
2019
Q1 		$4K Buy
445
+405
+1,013% +$3.08K ﹤0.01% 665
2018
Q4 		$0 Buy
+40
New +$281 ﹤0.01% 1087

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AG
Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Front Row Advisors's RDY Position: Q3 2020 in Review

Front Row Advisors sold out of Dr. Reddy's Laboratories (RDY) in Q3 2020, closing a stake of 510 shares — an estimated $5K sold.

Front Row Advisors first reported a position in RDY in Q4 2018 and held it in 7 quarters. The position peaked at $6K in Q4 2019. 186 funds tracked by Wall St. Rank hold RDY as of Q3 2020.

  • Front Row Advisors reported no remaining Dr. Reddy's Laboratories position as of Q3 2020 after selling out during the quarter.
  • Front Row Advisors sold 510 Dr. Reddy's Laboratories shares in Q3 2020, an estimated $5K.
  • Front Row Advisors first reported a position in Dr. Reddy's Laboratories in Q4 2018 and held it in 7 quarters.
  • Front Row Advisors's Dr. Reddy's Laboratories position peaked at $6K in Q4 2019.
  • 186 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2020.

Based on Front Row Advisors's 13F filing for Q3 2020, filed 30 Nov 2020.